Biotech Stock Surges on Bullish Analyst Coverage
01.10.2025 - 16:27:04Lucid Capital Sets Aggressive Revenue Target
A single research report from Lucid Capital sent Ocugen shares skyrocketing on Tuesday, with the biopharmaceutical company experiencing a dramatic 12% price surge following the firm’s bullish initiation. The sudden investor enthusiasm reflects growing confidence in Ocugen’s pipeline, particularly its lead therapeutic candidate.
Market strategist Elemer Piros at Lucid Capital established coverage of Ocugen with a “Buy” recommendation, focusing primarily on the company’s flagship drug candidate OCU400. This therapeutic targets Retinitis Pigmentosa, a progressive eye disease that can result in complete vision loss.
Piros projected that OCU400 could achieve peak sales reaching $3.2 billion by 2032. This optimistic assessment triggered exceptionally heavy trading activity, with volume nearly doubling the daily average—clear evidence of heightened investor attention.
